BiondVax Pharmaceuticals Ltd. (BVXV)
NASDAQ: BVXV · Delayed Price · USD
1.26
-0.01 (-0.79%)
At close: May 25, 2022 4:00 PM
1.32
0.06 (4.76%)
After-hours:May 25, 2022 4:05 PM EDT
Company Description
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel.
The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
BiondVax Pharmaceuticals Ltd.
| Country | Israel |
| Founded | 2003 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Employees | 15 |
| CEO | Ron Babecoff |
Contact Details
Address: Weizmann Science Park Po Box 4143 14 Einstein Street, Ness Ziona 7403618 Israel | |
| Phone | 972 8 930 2529 |
| Website | biondvax.com |
Stock Details
| Ticker Symbol | BVXV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | ILS |
| CIK Code | 0001611747 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer and Director |
| Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist |
| Joshua E. Phillipson B.Sc., M.B.A. | Director of Business Development and Investor Relations |
| Moran Ahdout Fruchter L.L.B. | Chief of Staff |
| Dalit Weinstein Fischer | Head of Technical Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 18, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 13, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 12, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 8, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 4, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 4, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 28, 2022 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] |
| Jan 11, 2022 | SC 13D/A | General statement of acquisition of beneficial ownership |
| Jan 11, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Dec 30, 2021 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| View All SEC Filings | ||